Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting

BRISBANE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Nathan Standifer Ph.D., Executive Director of Translational Science at Tempest, will present a poster at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting taking place March 15-17, 2023 in Denver, CO and virtually. The poster highlights biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist, showing an association between observed clinical benefit and fatty acid oxidation perturbations and gene expression. Poster presentation details: Title: TPST-1120, a first-in-human peroxisome-proliferator activated receptor-alpha (PPAR-α) antagonist: scientific rationale, clinical activity and biomarker assessments Date: Thursday, March 16, 2023 Time: 6:00 - 7:30 p.m. MT Abstract Number: 78 About Tempest Therapeutics Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company’s two novel clinical programs TPST-1120 and TPST-1495, target of PPARα and EP2/EP4, respectively, are advancing through trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com . Investor Contacts: Sylvia Wheeler Wheelhouse Life Science Advisors [email protected] Aljanae Reynolds Wheelhouse Life Science Advisors [email protected] ____________________ 1 If approved by the FDA © 2026 Tempest Therapeutics. All rights reserved. var s_CCSWebHostingAccount = "trcgtempesttherapeutics"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/9561","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNkeFuQyEIhV-ouTbN3oegstZdhRug2_r2tbqk7bJliz8U_ORwkIsCMtaLl2SBH6MFs0SCimdOpx3_CW4qeWARjQZRkrA9p1ykRtSRTCvl4qKQ0fuKlSzcj8urCjvxrNlQV_JBQqyS1jDkzUHRCx-7Qi94QvV_4QZD5Be2ETIoJWmt6_cHwo-1z9VL661jeA7H7YbH6fR2WPANPwFzhlTRDLCSuv3ApWHVwS6cuhVmmiPaSn45HPZB3km15NnwB0UrTsDSp0_zM77llq99Z90ztXCb_xUmCsI1","theme":"nir_pid4220","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"e4cd9886b98324d3a81033a7e8a58e5b662d9828a13ae2363f42a309d045dd8e"}}

The release as fetched from its publisher. tempesttx.com ↗